长春瑞滨联合卡培他滨治疗晚期乳腺癌的临床观察

Vinorelbine combined with capecitabine for advanced breast cancer

目的观察长春瑞滨联合卡培他滨治疗晚期乳腺癌的临床疗效和毒副反应。方法采用长春瑞滨与卡培他滨联合治疗,其中第1天与第8天给予长春瑞滨25mg/m2快速静脉滴注;第1-14天,卡培他滨1000mg/m^2,2次/d,21d为一周期,所有病例均接受至少2个周期的化疗。结果 28例患者入组,均为复治病例,均可行疗效及毒性评价,其中完全缓解1例（3.6%）,部分缓解12例（42.8%）,总有效率46.4%。主要毒副反应为骨髓毒性及手足综合征,均相对较轻。结论长春瑞滨联合卡培他滨方案治疗晚期乳腺癌有较好的疗效,毒副反应小,值得临床进一步研究。

Objective To investigate the efficacy and toxicity of vinorelbine（NVB）combined with capecitabine in the treatment of advanced breast cancer.Methods Twenty-eight patients were enrolled and treated previously.Vinorelbine 25 mg/m^2 was intravenously infused at day 1 and 8,and capecitabine 1 000 mg/m^2 was orally administered twice a day for 14 days,with 21 d as a cycle.All patients received the treatment for at least two cycles.All patients were included for observing the efficacy and adverse events.Results Of 28 patients,one（3.6%）of complete response and 12（42.8%）of partial responses were observed.The overall effective rate was 46.4%.The generally mild myelotoxicity and hand-foot syndrome were the main toxicity.Conclusion Vinorelbine combined with capcitabine could have a better effect for advanced breast cancer with less adverse effects.